Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GSK
GSK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GSK News
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
2d ago
seekingalpha
HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS
3d ago
moomoo
FDA Blocks Publication of Vaccine Safety Studies Amid Controversy
4d ago
CNBC
GSK Completes $950 Million Acquisition of 35Pharma to Enhance Pipeline
May 03 2026
Yahoo Finance
FDA Appoints New Acting Director for Biologics Center
May 01 2026
seekingalpha
Alector Discontinues Mid-Stage Alzheimer’s Trial for Latozinemab
Apr 30 2026
seekingalpha
GSK Reports Strong Q1 2026 Financials, Exceeds Expectations
Apr 29 2026
seekingalpha
AstraZeneca and GSK Q1 Earnings Beat Expectations
Apr 29 2026
CNBC
GSK Reports Q1 2026 Earnings with Strong Performance
Apr 29 2026
seekingalpha
GSK Reports Q1 Profit Growth with Strong EPS Increase
Apr 29 2026
NASDAQ.COM
Major Earnings Reports Expected Before Wednesday's Open
Apr 28 2026
seekingalpha
GSK Q1 Earnings Announcement Scheduled
Apr 28 2026
seekingalpha
GSK Receives FDA Priority Review for Hepatitis B Therapy
Apr 28 2026
seekingalpha
FDA Accepts Priority Review for Bepirovirsen by GSK and Ionis
Apr 28 2026
NASDAQ.COM
GSK, IONIS PARTNER, ANNOUNCES BEPIROVIRSEN RECEIVES PRIORITY REVIEW AND BREAKTHROUGH THERAPY DESIGNATION FROM U.S. FDA AS A POTENTIAL FIRST-IN-CLASS TREATMENT FOR CHRONIC HEPATITIS B
Apr 28 2026
moomoo
Tesaro and AnaptysBio Litigation Update
Apr 27 2026
seekingalpha
Show More News
